Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

cetuximab

View Patient Information
A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Anti-EGFR Monoclonal Antibody
Anti-Epidermal Growth Factor Receptor Monoclonal Antibody
C225 monoclonal antibody
cetuximab biosimilar CDP-1
cetuximab biosimilar CMAB009
cetuximab biosimilar KL 140
Chimeric Anti-EGFR Monoclonal Antibody
Chimeric Monoclonal Antibody C225
Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 gamma1-chain), disulfide with human-mouse monoclonal C225 kappa-chain, dimer
monoclonal antibody C225
US brand name:Erbitux
Abbreviation:Chimeric MoAb C225
MOAB C225
Code name:C225
IMC-C225
IND number:11460
3610
NSC code:714692
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search